Answers are grounded in this paper and cite their sources.
Interview explores bispecific antibody-drug conjugates targeting tumor heterogeneity, highlighting design and safety implications.
“...we know that the specificity of our antibodies and their controlled conjugation helps us target tumor tissue while avoiding engagement with healthy tissues...”Lauren Coyle, Launch Commissioning Editor, Bioconjugate Insights, speaks with Sarka Stehlikova, Director, Biologics Core Technologies, SOTIO, about the design of bispecific ADCs for addressing tumor heterogeneity. They discuss the importance of site-specific conjugation and DAR control, and how precise payload placement influences stability and safety in complex ADC architectures.
No takes yet. Share an insight, caveat, or question.
Šárka Stehlíková (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: